Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$41.27
+1.6%		$42.89
$14.25
▼
$48.51
$4.48B0.321.23 million shs365,966 shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$24.69
-1.1%		$24.98
$6.69
▼
$34.39
$4.17B1.123.37 million shs960,812 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.39
-3.7%		$33.54
$25.77
▼
$43.15
$3.95B0.693.06 million shs2.76 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$18.70
-2.0%		$22.12
$6.50
▼
$42.75
$1.11B1.711.07 million shs416,714 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
+3.91%-0.80%-2.51%+2.94%+151.07%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
+2.31%+2.18%+9.39%-15.19%+197.43%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+2.48%-21.73%-0.55%-12.93%+24.05%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+4.09%-1.50%-15.12%-7.33%-60.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$41.27
+1.6%		$42.89
$14.25
▼
$48.51
$4.48B0.321.23 million shs365,966 shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$24.69
-1.1%		$24.98
$6.69
▼
$34.39
$4.17B1.123.37 million shs960,812 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.39
-3.7%		$33.54
$25.77
▼
$43.15
$3.95B0.693.06 million shs2.76 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$18.70
-2.0%		$22.12
$6.50
▼
$42.75
$1.11B1.711.07 million shs416,714 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
+3.91%-0.80%-2.51%+2.94%+151.07%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
+2.31%+2.18%+9.39%-15.19%+197.43%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
+2.48%-21.73%-0.55%-12.93%+24.05%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+4.09%-1.50%-15.12%-7.33%-60.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.82
Moderate Buy$51.3324.40% Upside
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
2.75
Moderate Buy$43.4676.06% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.75
Moderate Buy$99.67217.48% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90
Moderate Buy$41.71123.13% Upside

Current Analyst Ratings Breakdown

Latest VOR, EWTX, TNGX, and VKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$83.00 ➝ $87.00
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$120.00
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/21/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $57.00
9/14/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
8/20/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$53.00 ➝ $60.00
8/18/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$66.00 ➝ $68.00
8/18/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/12/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $35.00
8/12/2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$18.00 ➝ $27.00
(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.93 per shareN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$62.38M66.72N/AN/A$2.57 per share9.61
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$5.65 per shareN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$167.79M-$1.85N/AN/AN/AN/A-39.01%-36.96%11/5/2026 (Estimated)
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$101.59M-$0.85N/AN/AN/AN/A-25.75%-23.36%11/3/2026 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.66N/AN/AN/AN/A-94.56%-82.75%10/28/2026 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest VOR, EWTX, TNGX, and VKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.07N/AN/AN/AN/AN/A
8/11/2026Q2 2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.3172-$0.37-$0.0528-$0.37$1.56 millionN/A
8/11/2026Q2 2026
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.69-$0.80-$0.11-$1.16N/AN/A
8/6/2026Q2 2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.4677-$0.53-$0.0623-$0.53N/AN/A
7/29/2026Q2 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.21-$1.10+$0.11-$1.10N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
16.24
16.24
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/A
50.82
50.82
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
4.72
4.72
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
78.99%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
21.30%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
6.50%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
127108.60 million85.47 millionOptionable
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
137168.61 million157.65 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
65125.99 million119.31 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
7659.16 million59.00 millionN/A

Recent News About These Companies

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened
September 30 at 11:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-jumps-53-heres-what-happened-2026-09-30/
Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 7:33 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69706309-vor-biopharma-telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis-399.htm
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 12:59 PM  |  marketscreener.comM
Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes
September 29 at 12:59 PM  |  boursorama.comB
Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 29 at 8:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3370807/0/en/telitacicept-demonstrates-deep-and-durable-minimal-symptom-expression-through-48-weeks-in-generalized-myasthenia-gravis.html
Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus
September 29 at 7:59 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VOR/pressreleases/4850802/vor-biopharma-vor-gets-a-buy-from-stifel-nicolaus/
Vor Biopharma Inc. (NASDAQ:VOR) Stock Rated "Moderate Buy" by Sell-Side Brokerages
September 28 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056562
Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages
September 28 at 2:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-vor-biopharma-inc-nasdaq-vor-stock-has-average-price-target-of-4171-according-to-brokerages-2026-09-28/
【VOR】Vor Biopharma
September 23, 2026  |  note.comN
Vor Biopharma no fórum Stifel 2026: telitacicept aposta em dupla estratégia
September 23, 2026  |  br.investing.comhttps://br.investing.com/news/transcripts/vor-biopharma-no-forum-stifel-2026-telitacicept-aposta-em-dupla-estrategia-93CH-2073344
Vor Biopharma在Stifel 2026论坛上阐述telitacicept双路径布局
September 23, 2026  |  cn.investing.comhttps://cn.investing.com/news/transcripts/article-93CH-3580464
Vor Biopharma al forum Stifel 2026: telitacicept punta su doppia strategia
September 23, 2026  |  it.investing.comhttps://it.investing.com/news/transcripts/vor-biopharma-al-forum-stifel-2026-telitacicept-punta-su-doppia-strategia-93CH-3560029
Vor Biopharma en foro Stifel 2026: telitacicept avanza en doble vía
September 23, 2026  |  mx.investing.comhttps://mx.investing.com/news/transcripts/vor-biopharma-en-foro-stifel-2026-telitacicept-avanza-en-doble-via-93CH-3774116
Vor Biopharma (NASDAQ:VOR) Shares Down 8.2% - Should You Sell?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-shares-down-82-should-you-sell-2026-09-23/
Vor Biopharma (NASDAQ:VOR) Trading Up 6.1% - Still a Buy?
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-trading-up-61-still-a-buy-2026-09-22/
Vor Biopharma: A Funded Replication Story With Franchise Potential
September 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947759-vor-biopharma-a-funded-replication-story-with-franchise-potential
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
September 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VOR/latest-news/
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944756-vor-biopharma-inc-vor-presents-at-citigroups-biopharma-back-to-school-summit-2026-transcript
Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.4% - Should You Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-vor-biopharma-nasdaq-vor-stock-price-down-54-should-you-sell-2026-09-09/
97,722 Shares in Vor Biopharma Inc. $VOR Purchased by Bank of New York Mellon Corp
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-97722-shares-in-vor-biopharma-inc-vor-purchased-by-bank-of-new-york-mellon-corp-2026-09-09/
Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis
September 8, 2026  |  marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Split image showing a GameStop store checkout counter beside a laptop displaying the eBay website, with a graded Pokémon card nearby.
GameStop’s Comeback Case Is Getting Interesting, But eBay Still Looks Stronger
By Thomas Hughes | September 10, 2026
Dell logo illuminated in a data center setting with a laptop and server racks visible nearby.
One of Trump's Favorite Stocks Just Reported Blowout Earnings
By Jessica Mitacek | September 3, 2026
A fighter jet with open engine panels sits on an aircraft carrier deck at sunset, with the ship's superstructure visible in the background.
Defense Stocks Are Pulling Back as Their Navy Tailwinds Get Stronger
By Jeffrey Neal Johnson | September 4, 2026
A hard disk drive stands upright on a server rack in a data center aisle lined with illuminated equipment.
5 Buy-and-Hold Stocks Built to Weather a Volatile Market
By Chris Markoch | September 16, 2026
Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$41.26 +0.67 (+1.64%)
As of 01:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Tango Therapeutics stock logo

Tango Therapeutics NASDAQ:TNGX

$24.68 -0.27 (-1.06%)
As of 01:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$31.39 -1.21 (-3.70%)
As of 01:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Vor Biopharma stock logo

Vor Biopharma NASDAQ:VOR

$18.70 -0.39 (-2.02%)
As of 01:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas